GT 2016Selective H3 antagonist CAS# 152241-24-2 |
- S/GSK1349572
Catalog No.:BCC2138
CAS No.:1051375-16-6
- Atazanavir
Catalog No.:BCC3622
CAS No.:198904-31-3
- Raltegravir (MK-0518)
Catalog No.:BCC2137
CAS No.:518048-05-0
- BMS-538203
Catalog No.:BCC4136
CAS No.:543730-41-2
- Elvitegravir (GS-9137)
Catalog No.:BCC2134
CAS No.:697761-98-1
- MK-2048
Catalog No.:BCC2136
CAS No.:869901-69-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 152241-24-2 | SDF | Download SDF |
| PubChem ID | 9839975 | Appearance | Powder |
| Formula | C19H31N3O | M.Wt | 317.47 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
| Chemical Name | 5-cyclohexyl-1-[4-(1H-imidazol-5-yl)piperidin-1-yl]pentan-1-one | ||
| SMILES | C1CCC(CC1)CCCCC(=O)N2CCC(CC2)C3=CN=CN3 | ||
| Standard InChIKey | YTCGNPGLMAECND-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C19H31N3O/c23-19(9-5-4-8-16-6-2-1-3-7-16)22-12-10-17(11-13-22)18-14-20-15-21-18/h14-17H,1-13H2,(H,20,21) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | High affinity H3 receptor antagonist (Ki = 43.8 nM). Displays selectivity against H1 and H2 receptors (IC50 >10 μM). Increases the release of histamine in the cerebral cortex. Displays no activity at histamine methyltransferase in vitro at concentrations up to 3 μM. Brain penetrant. |
GT 2016 Dilution Calculator
GT 2016 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1499 mL | 15.7495 mL | 31.499 mL | 62.9981 mL | 78.7476 mL |
| 5 mM | 0.63 mL | 3.1499 mL | 6.2998 mL | 12.5996 mL | 15.7495 mL |
| 10 mM | 0.315 mL | 1.575 mL | 3.1499 mL | 6.2998 mL | 7.8748 mL |
| 50 mM | 0.063 mL | 0.315 mL | 0.63 mL | 1.26 mL | 1.575 mL |
| 100 mM | 0.0315 mL | 0.1575 mL | 0.315 mL | 0.63 mL | 0.7875 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- SB 204741
Catalog No.:BCC7035
CAS No.:152239-46-8
- Aphadilactone C
Catalog No.:BCN7645
CAS No.:1522004-70-1
- Aphadilactone B
Catalog No.:BCN7646
CAS No.:1522004-68-7
- Forrestin A
Catalog No.:BCN1677
CAS No.:152175-76-3
- A 80426 mesylate
Catalog No.:BCC7336
CAS No.:152148-64-6
- PD 169316
Catalog No.:BCC3969
CAS No.:152121-53-4
- SB 203580
Catalog No.:BCC3663
CAS No.:152121-47-6
- SB202190 (FHPI)
Catalog No.:BCC1093
CAS No.:152121-30-7
- N,N'-Di-Boc-1H-pyrazole-1-carboxamidine
Catalog No.:BCC9065
CAS No.:152120-54-2
- 2-chloro-11-cyclopentyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one
Catalog No.:BCC8568
CAS No.:1521197-43-2
- Teuclatriol
Catalog No.:BCN1676
CAS No.:152110-17-3
- 1,2-Epoxy-1-hydroxymethylpyrrolizidine
Catalog No.:BCN1557
CAS No.:15211-03-7
- Uncargenin C
Catalog No.:BCN1678
CAS No.:152243-70-4
- Mupinensisone
Catalog No.:BCN4704
CAS No.:152253-67-3
- U 93631
Catalog No.:BCC7471
CAS No.:152273-12-6
- Amyloid β-Peptide (10-20) (human)
Catalog No.:BCC1026
CAS No.:152286-31-2
- (S)-4-(4-Aminobenzyl)-2(1H)-oxazolidinone
Catalog No.:BCC8400
CAS No.:152305-23-2
- Gnetulin
Catalog No.:BCN3401
CAS No.:152340-24-4
- SAR405
Catalog No.:BCC4006
CAS No.:1523406-39-4
- Fmoc-D-Phe(4-OMe)-OH
Catalog No.:BCC2632
CAS No.:152436-04-9
- Imatinib (STI571)
Catalog No.:BCC4979
CAS No.:152459-95-5
- N-(2-Methyl-5-nitrophenyl)-4- (pyridin-3-yl)pyrimidin-2-amine
Catalog No.:BCC9055
CAS No.:152460-09-8
- N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine
Catalog No.:BCC9059
CAS No.:152460-10-1
- Leachianone G
Catalog No.:BCN3308
CAS No.:152464-78-3
Pharmacological characterization of GT-2016, a non-thiourea-containing histamine H3 receptor antagonist: in vitro and in vivo studies.[Pubmed:7473144]
J Pharmacol Exp Ther. 1995 Nov;275(2):598-604.
GT-2016, a non-thiourea-containing imidazole, has been developed as a histamine H3 antagonist. In vitro and in vivo studies in rats were conducted to characterize receptor selectivity and autoreceptor functionality for GT-2016. GT-2016 demonstrated high affinity (43.8 +/- 3.0 nM) and selectivity for the histamine H3 receptor in vitro. In vivo, GT-2016 (3, 10 and 30 mg/kg i.p. and p.o.) was shown to cross the blood-brain barrier and dose-dependently bind to cortical histamine H3 receptors. GT-2016 induced dose-dependent increases in histamine turnover at concentrations that exhibited significant histamine H3 receptor occupancy. Also, in vivo microdialysis experiments were conducted in awake, freely moving rats treated with GT-2016. GT-2016 (10 and 30 mg/kg i.p.) increased histamine release by approximately 75% above baseline within 1 hr, and elevated histamine release was observed for up to 2.5 hr after the higher dose. In contrast, GT-2016 was devoid of activity on histamine methyltransferase in vitro at concentrations up to 3 microM. Taken together, the results show that GT-2016 crosses the blood-brain barrier, binds to H3 receptors and increases the release of histamine in the cerebral cortex, consistent with blockade of presynaptic H3 autoreceptors. In summary, these findings allowed us to identify and characterize the in vitro and in vivo biochemical properties of a novel H3 receptor antagonist, GT-2016.
Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.[Pubmed:10215700]
J Pharmacol Exp Ther. 1999 May;289(2):1160-8.
Previously, a novel series of 1H-4-substituted imidazole compounds were described as potent and selective histamine (HA) H3 receptor ligands (Yates et al., 1999). The present studies extend the structure-activity relationships for optimal HA H3 receptor affinity and central nervous system penetration by incorporation of a conformationally restricted cyclopropane nucleus. Moreover, the current studies extend our understanding of ligand-receptor interactions at the HA H3 receptor with the development of high affinity HA H3 receptor antagonists containing a stereochemical presentation. Structure-activity relationships were established from in vitro HA H3 receptor-binding affinities using [3H]Nalpha-methylhistamine and rat cortical tissue homogenates. Systematic optimization of multiple structural features critical for HA H3 receptor affinity provided some of the most potent HA H3 receptor agents described. For example, GT-2331 was determined to bind to a single population of HA H3 receptors with a Ki of 0.125 nM. In vivo, GT-2331 has a favorable central nervous system penetration profile with an ED50 of 0.08 mg/kg (i.p.) in rats and a long duration of action (T1/2 > 4 h). In addition, GT-2331 was extremely selective for the HA H3 receptor versus other HA receptors and a battery of neurotransmitter, neuropeptide, hormone, or enzyme systems. Several compounds were tested in vitro which suggested HA H3 receptor heterogeneity and are discussed in terms of structure-activity relationships for the HA H3 receptor.
Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.[Pubmed:10215699]
J Pharmacol Exp Ther. 1999 May;289(2):1151-9.
A new series of 1H-4-substituted imidazole compounds were synthesized and identified as potent and selective histamine (HA) H3 receptor ligands. These ligands establish that HA H3 antagonists exhibit stereoselective and conformational preferences in their binding to the HA H3 receptor. Structure-activity relationships were determined in vitro by HA H3 receptor-binding affinities using [3H]Nalpha-methylhistamine and rat cerebral cortical tissue homogenates. Several derivatives containing olefin, amide, and acetylene functional groups were identified as potent HA H3 receptor ligands. In the olefin series, GT-2227 (4-(6-cyclohexylhex-cis-3-enyl)imidazole) was identified as a potent HA H3 receptor ligand with a Ki of 4.2 +/- 0.6 nM, while the trans isomer (GT-2228) displayed a reduced potency (Ki = 15.2 +/- 2.4 nM). GT-2227 was also found to have excellent central nervous system penetration in an ex vivo binding paradigm (ED50 = 0.7 mg/kg i.p.). In the acetylene series, GT-2260 and GT-2286 both exhibited high affinity (Ki = 2.9 +/- 0.2 and 0.95 +/- 0.3 nM) and excellent central nervous system penetration profiles (ED50 = 0.43 and 0.48 mg/kg i.p., respectively). As a prototype for the series, GT-2227 showed high affinity for the human HA H3 receptor (3.2 nM) and minimal affinity for the human HA H1 (Ki = 13,407 +/- 540 nM) and H2 (Ki = 4,469 +/- 564 nM) receptor subtypes. GT-2227 also showed good selectivity for the HA H3 receptor over a broad spectrum of other neurotransmitter receptors (IC50 >/= 1 microM). Furthermore, GT-2227 improved acquisition in a cognitive paradigm without behavioral excitation or effect on spontaneous locomotor activity. In summary, the present studies demonstrate the development of novel HA H3-selective ligands, and lend support for the use of such agents in the treatment of disorders associated with cognitive or attentional deficits.
